TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03219047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given at standard dose and schedule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Derived Xenograft
Description: Xenograft developed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Derived Xenograft
Description: Xenograft developed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Medicine
Description: Receive treatment based on the results of the PDX models

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Medicine
Description: Receive treatment based on the results of the PDX models
Study: NCT03697551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan
Description: Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
Study: NCT02605551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Therapy
Description: All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~1. OM Occipitomastoid release technique~2. Sub-Occipital Release Technique~3. Rib Raising Technique~4. Rotatory stimulation of posterior Chapman's Reflexes~5. Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
Study: NCT00415051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVF MP-12
Description: Administer 1 ml SQ
Study: NCT00508313

Intervention type: PROCEDURE
Intervention: Thermal Imaging
Description: Thermal imaging sessions, each taking approximately 10 minutes.

Intervention type: PROCEDURE
Intervention: Thermal Imaging
Description: Thermal imaging sessions, each taking approximately 10 minutes.
Study: NCT05101824

Intervention type: RADIATION
Group type: OTHER
Intervention: SABR
Description: Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
Study: NCT00744562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-21M18
Description: 0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
Study: NCT03020459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peeling-reposition
Description: After dying with Brilliant Blue G (BBG, Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to maintain facedown position for two weeks postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peeling
Description: After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for two weeks postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilliant Blue G
Description: We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilliant Blue G
Description: We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postoperative posture
Description: Patients of both two groups need to keep prone position for two weeks after the operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative posture
Description: Patients of both two groups need to keep prone position for two weeks after the operation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constellation 23-gauge vitrectomy system
Description: All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constellation 23-gauge vitrectomy system
Description: All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
Study: NCT00418769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT00002610

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02266446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention & Interpretation Modification
Study: NCT00750113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifidipine
Description: Tablets 20 Mg daily for 4 weeks then combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Tablets 80 Mg daily for 4 weeks then combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine/Telmisartan
Description: 2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
Study: NCT03805737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amulez and sunlight
Description: Amulez and sun exposure for 2 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amulez and red light treatment
Description: Amulez and red light treatment for 10 minutes
Study: NCT04583605

Intervention type: DEVICE
Intervention: PREVENA
Description: A negative pressure wound closure therapy is used after lymph node dissection
Study: NCT04263753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder conservative surgery in placenta accretta
Description: After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~\* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~\* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20
Study: NCT05956275

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tramadol
Description: ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morfin
Description: No block was applied to the patients in control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morfin
Description: No block was applied to the patients in control
Study: NCT03581903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N3 pLAIV
Description: Approximately 10\^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 pIIV
Description: 30 micrograms administered by intramuscular (IM) injection
Study: NCT01486290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
Study: NCT00886795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept (Orencia ®)
Description: 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
Study: NCT02060370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
Study: NCT00261755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Group
Description: All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
Study: NCT04604834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFAT first
Description: Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFAT first
Description: Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APRP first
Description: Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APRP first
Description: Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
Study: NCT03869372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
Study: NCT04541563

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fisher Wallace Cranial Electrotherapy Stimulator Device
Description: Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
Study: NCT02703259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Study: NCT04541563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher Wallace Cranial Electrotherapy Stimulator Device
Description: Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
Study: NCT02703259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study: NCT02837003

Intervention type: DRUG
Intervention: Aspirin
Description: Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Study: NCT04564001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
Study: NCT01200706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: amoxicillin 50mg/kg/day given in two different administration schemes
Study: NCT02837003

Intervention type: DRUG
Intervention: Thienopyridine
Description: Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Study: NCT01565278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil (Standard treatment)
Description: 1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soybean oil + Fish oil
Description: Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
Study: NCT03198468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Thermal Vapor Ablation
Description: Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).
Study: NCT03847740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric Trumb Force handle
Description: Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric Trumb Force handle
Description: Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
Study: NCT04166604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery
Study: NCT01622933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine + IFN
Description: Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVTMM2/DC Vaccination
Description: Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
Study: NCT02021292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10 mg, oral tablet, to be taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet, to be taken once daily.
Study: NCT04331691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
Study: NCT00370500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
Study: NCT05504317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
Study: NCT02353026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Artesunate
Description: Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
Study: NCT01885013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Myocet + Cyclophosphamide
Description: Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet + Cyclophosphamide
Description: Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles
Study: NCT04479839

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of the airway
Description: Placing ultrasound on the neck after intubation

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of the airway
Description: Placing ultrasound on the neck after intubation
Study: NCT00676403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study: NCT05259488

Intervention type: DIETARY_SUPPLEMENT
Intervention: immunonutrition
Description: nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
Study: NCT01162616

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: labeled iron solutions
Description: labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
Study: NCT03999502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
Study: NCT02150928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Description: * Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit
Study: NCT00924924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act Healthy!
Description: Six-week class of 50 minute sessions of self-management training for health behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Act Healthy!
Description: Six-week class of 50 minute sessions of self-management training for health behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed treatment control
Description: Delayed self-management training group - begins following completion of the experimental group training